Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model

David OJ(2001)Limited sampling strategies for estimating cyclosporin area under the concentration–time curve: review of current algorithms Ther Drug Monit 23 100-114

Johnston A(2001)Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs Comput Methods Prog Biomed 65 141-151

Retout S(2003)An evaluation of population D-optimal designs via pharmacokinetic simulations Ann Biomed Eng 31 98-111

Duffull S(2016)Interaction between darunavir and etravirine is partly mediated by CYP3A5 polymorphism PLoS One 11 e0165631-174

Mentré F(2008)Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection Clin Chem 55 170-63

Hooker AC(2011)Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children Clin Pharmacokinet 50 51-94

Foracchia M(2004)Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming Comput Methods Prog Biomed 75 85-2049

Dodds MG(2006)Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide Pharm Res 23 2036-65

Vicini P(2010)Evaluation of different tests based on observations for external model evaluation of population analyses J Pharmacokinet Pharmacodyn 37 49-166

Belkhir L(2008)Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R Comput Methods Prog Biomed 90 154-46

David OJ(2001)Limited sampling strategies for estimating cyclosporin area under the concentration–time curve: review of current algorithms Ther Drug Monit 23 100-114

Johnston A(2001)Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs Comput Methods Prog Biomed 65 141-151

Retout S(2003)An evaluation of population D-optimal designs via pharmacokinetic simulations Ann Biomed Eng 31 98-111

Duffull S(2016)Interaction between darunavir and etravirine is partly mediated by CYP3A5 polymorphism PLoS One 11 e0165631-174

Mentré F(2008)Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection Clin Chem 55 170-63

Hooker AC(2011)Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children Clin Pharmacokinet 50 51-94

Foracchia M(2004)Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming Comput Methods Prog Biomed 75 85-2049

Dodds MG(2006)Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide Pharm Res 23 2036-65

Vicini P(2010)Evaluation of different tests based on observations for external model evaluation of population analyses J Pharmacokinet Pharmacodyn 37 49-166

Belkhir L(2008)Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R Comput Methods Prog Biomed 90 154-46